New drug targets dangerous fat levels in blood

NCT ID NCT03783377

First seen Jan 11, 2026 · Last updated May 09, 2026 · Updated 23 times

Summary

This early-stage study tested a new medicine called ARO-APOC3 in healthy people and those with extremely high triglycerides (blood fats), including a rare genetic condition called familial chylomicronemia syndrome. The main goal was to check safety and how the drug moves through the body. 112 participants received single or multiple doses to find the right dose and see if it lowers fat levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site 10

    Papatoetoe, Auckland, 2025, New Zealand

  • Research Site 11

    Christchurch, 8011, New Zealand

  • Research Site 2

    Camperdown, New South Wales, 2050, Australia

  • Research Site 3

    Adelaide, South Australia, 5000, Australia

  • Research Site 4

    Perth, Washington, 6009, Australia

  • Research Site 5

    Sippy Downs, Queensland, Australia

  • Research Site 6

    Chicoutimi, Quebec, G7H 7K9, Canada

  • Research Site 7

    London, Ontario, N6A 5B7, Canada

  • Research Site 8

    Montreal, Quebec, H2W 1R7, Canada

  • Research Site 9

    Grafton, Auckland, 1010, New Zealand

Conditions

Explore the condition pages connected to this study.